Ascendis Pharma A/S (NASDAQ:ASND) Stock Price Expected to Rise, JPMorgan Chase & Co. Analyst Says

Ascendis Pharma A/S (NASDAQ:ASND) had its price target lifted by stock analysts at JPMorgan Chase & Co. from $165.00 to $167.00 in a report issued on Wednesday,Benzinga reports. The brokerage currently has an “overweight” rating on the biotechnology company’s stock. JPMorgan Chase & Co.‘s price target would indicate a potential upside of 29.09% from the company’s previous close.

Other research analysts have also issued research reports about the company. Oppenheimer decreased their target price on Ascendis Pharma A/S from $190.00 to $180.00 and set an “outperform” rating for the company in a research report on Friday, November 15th. StockNews.com upgraded shares of Ascendis Pharma A/S from a “sell” rating to a “hold” rating in a research note on Wednesday, November 20th. TD Cowen decreased their target price on Ascendis Pharma A/S from $160.00 to $153.00 and set a “buy” rating for the company in a research report on Friday, November 15th. Stifel Nicolaus boosted their target price on shares of Ascendis Pharma A/S from $200.00 to $207.00 and gave the company a “buy” rating in a research note on Friday, November 15th. Finally, Wedbush reiterated an “outperform” rating and issued a $181.00 price objective on shares of Ascendis Pharma A/S in a research note on Friday, November 15th. Two research analysts have rated the stock with a hold rating and thirteen have issued a buy rating to the company’s stock. According to MarketBeat, Ascendis Pharma A/S currently has an average rating of “Moderate Buy” and an average price target of $191.57.

Ascendis Pharma A/S Trading Up 2.6 %

Shares of NASDAQ:ASND opened at $129.37 on Wednesday. The stock has a market capitalization of $7.85 billion, a P/E ratio of -16.01 and a beta of 0.65. The stock’s 50-day moving average price is $133.46 and its 200-day moving average price is $133.07. Ascendis Pharma A/S has a 12-month low of $111.09 and a 12-month high of $161.00.

Institutional Trading of Ascendis Pharma A/S

A number of institutional investors and hedge funds have recently bought and sold shares of the stock. abrdn plc grew its position in shares of Ascendis Pharma A/S by 18.3% during the fourth quarter. abrdn plc now owns 187,180 shares of the biotechnology company’s stock valued at $25,769,000 after purchasing an additional 28,967 shares in the last quarter. China Universal Asset Management Co. Ltd. grew its holdings in Ascendis Pharma A/S by 14.8% during the 4th quarter. China Universal Asset Management Co. Ltd. now owns 12,789 shares of the biotechnology company’s stock valued at $1,761,000 after buying an additional 1,647 shares in the last quarter. Gilbert & Cook Inc. increased its stake in Ascendis Pharma A/S by 72.5% in the 4th quarter. Gilbert & Cook Inc. now owns 4,421 shares of the biotechnology company’s stock worth $609,000 after acquiring an additional 1,858 shares during the last quarter. Blue Trust Inc. boosted its position in shares of Ascendis Pharma A/S by 540.5% during the 4th quarter. Blue Trust Inc. now owns 506 shares of the biotechnology company’s stock valued at $76,000 after acquiring an additional 427 shares during the last quarter. Finally, SG Americas Securities LLC grew its holdings in shares of Ascendis Pharma A/S by 410.4% in the fourth quarter. SG Americas Securities LLC now owns 33,944 shares of the biotechnology company’s stock valued at $4,673,000 after purchasing an additional 27,293 shares in the last quarter.

About Ascendis Pharma A/S

Ascendis Pharma A/S, a biopharmaceutical company, focuses on developing therapies for unmet medical needs. It offers SKYTROFA for treating patients with growth hormone deficiency (GHD). The company is also developing a pipeline of three independent endocrinology rare disease product candidates in clinical development, as well as focuses on advancing oncology therapeutic candidates.